IL94167A - Immunoconjugate targeting 15A8 or ZME-018 antigens and comprising TNF or interleukin-1 - Google Patents

Immunoconjugate targeting 15A8 or ZME-018 antigens and comprising TNF or interleukin-1

Info

Publication number
IL94167A
IL94167A IL9416790A IL9416790A IL94167A IL 94167 A IL94167 A IL 94167A IL 9416790 A IL9416790 A IL 9416790A IL 9416790 A IL9416790 A IL 9416790A IL 94167 A IL94167 A IL 94167A
Authority
IL
Israel
Prior art keywords
tnf
zme
interleukin
antigens
biological response
Prior art date
Application number
IL9416790A
Other languages
English (en)
Other versions
IL94167A0 (en
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL94167A0 publication Critical patent/IL94167A0/xx
Publication of IL94167A publication Critical patent/IL94167A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL9416790A 1989-05-05 1990-04-23 Immunoconjugate targeting 15A8 or ZME-018 antigens and comprising TNF or interleukin-1 IL94167A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34823789A 1989-05-05 1989-05-05

Publications (2)

Publication Number Publication Date
IL94167A0 IL94167A0 (en) 1991-01-31
IL94167A true IL94167A (en) 1997-02-18

Family

ID=23367161

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9416790A IL94167A (en) 1989-05-05 1990-04-23 Immunoconjugate targeting 15A8 or ZME-018 antigens and comprising TNF or interleukin-1

Country Status (19)

Country Link
EP (1) EP0396387B1 (de)
JP (1) JP3589459B2 (de)
KR (1) KR0181294B1 (de)
CN (1) CN1072505C (de)
AT (1) ATE98873T1 (de)
AU (1) AU645747B2 (de)
CA (1) CA2015060C (de)
DE (1) DE69005352T2 (de)
DK (1) DK0396387T3 (de)
ES (1) ES2060947T3 (de)
FI (1) FI100092B (de)
HK (1) HK1006678A1 (de)
IE (1) IE63847B1 (de)
IL (1) IL94167A (de)
NO (1) NO301168B1 (de)
NZ (1) NZ233413A (de)
PT (1) PT93966B (de)
SA (1) SA90110099B1 (de)
ZA (1) ZA902949B (de)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2073964A1 (en) * 1990-02-06 1991-08-07 Naoru Hamaguchi Immune complexes
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
WO1992003569A1 (en) * 1990-08-29 1992-03-05 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
WO1992008801A1 (en) * 1990-11-09 1992-05-29 Abbott Laboratories Bridging antibody fusion constructs
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU1643692A (en) * 1991-03-07 1992-10-06 Seragen, Inc. Use of cell surface receptor targeted molecules for the treatment of viral diseases
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
DE69226197T2 (de) * 1991-11-08 1999-02-11 Somatogen, Inc., Boulder Hämoglobine als arzneimittelabgabesystem
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
ES2166368T3 (es) * 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
DK0706799T3 (da) * 1994-09-16 2002-02-25 Merck Patent Gmbh Immunkonjugater II
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
DK0929578T3 (da) * 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
ATE267215T1 (de) 1997-12-08 2004-06-15 Lexigen Pharm Corp Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
EP1982990A1 (de) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Zytokinrezeptor wie eine gemeinsame Gammakette
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
MXPA02012434A (es) 2000-06-16 2004-09-06 Cambridge Antibody Tech Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
WO2001097844A1 (en) * 2000-06-22 2001-12-27 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
PL358582A1 (en) 2000-06-29 2004-08-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
TWI327600B (en) 2000-11-28 2010-07-21 Medimmune Llc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
MXPA03009924A (es) 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
ES2437992T3 (es) 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
DK1414471T3 (da) 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
EP2270049A3 (de) 2002-04-12 2011-03-09 Medimmune, Inc. Rekombinante Anti-Interleukin-9-Antikörper
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP2070949B1 (de) 2002-06-10 2013-01-16 Vaccinex, Inc. C35-Antikörper und ihre Verwendung zur Behandlung von Krebs
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
EP1572748B1 (de) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
EP1585815A4 (de) 2003-01-21 2006-02-22 Bristol Myers Squibb Co Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
EP2266628A3 (de) 2003-05-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Methode zur Bestimmung der Anfälligkeit für Knochenmetastasen über die Expression von EPhA2
ES2775204T3 (es) 2003-12-23 2020-07-24 Genentech Inc Nuevos anticuerpos anti IL13 y usos de los mismos
DK1699822T3 (da) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
JP2008504008A (ja) 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
EP1702069A2 (de) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Auf onkofötales fibronectin gerichtetes interleukin-12
EP1776136B1 (de) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
MXPA06014691A (es) * 2004-06-30 2008-03-11 Novartis Ag Conjugados de anticuerpo y derivados de duocarmicina como agentes anti-tumorales.
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
DE602005020837D1 (de) 2004-12-09 2010-06-02 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
US8165517B2 (en) 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
SI2500030T2 (sl) 2005-11-04 2018-11-30 Genentech, Inc. Uporaba inhibitorjev komplementarnih procesov za zdravljenje očesnih bolezni
AU2006311828B2 (en) 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
EP1945261A4 (de) 2005-11-07 2010-05-12 Scripps Research Inst Zusammensetzungen und verfahren zur steuerung der spezifität von gewebefaktor-signalisierungen
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
BRPI0710616A2 (pt) 2006-04-13 2011-08-16 Novartis Vaccines & Diagnostic métodos para tratar, diagnosticar ou detectar cáncer
RU2461572C2 (ru) 2006-06-07 2012-09-20 Биоэллаенс К.В. Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
JP5386364B2 (ja) 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
ES2439490T3 (es) 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
PL2068887T3 (pl) 2007-01-09 2014-09-30 Biogen Ma Inc Przeciwciała przeciw sp35 i ich zastosowanie
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
SG178744A1 (en) 2007-02-02 2012-03-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
JP2010521180A (ja) 2007-03-14 2010-06-24 ノバルティス アーゲー 癌を処置、診断または検出するためのａｐｃｄｄ１阻害剤
US20130195881A1 (en) 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
HUE037489T2 (hu) 2007-08-29 2018-08-28 Sanofi Sa Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
EP3002298B1 (de) 2007-11-21 2019-08-28 Oregon Health & Science University Anti-faktor xi monoklonale antikörper und verfahren zur verwendung davon
RU2528738C2 (ru) 2007-12-18 2014-09-20 Биоэллаенс К.В. Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
CA2720048A1 (en) 2008-04-16 2009-10-22 Biogen Idec Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
AU2008361352B2 (en) 2008-09-07 2013-05-09 Glyconex Inc. Anti-extended Type I glycosphingolipid antibody, derivatives thereof and use
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
JP6059013B2 (ja) 2009-05-08 2017-01-11 バクシネックス インコーポレーティッド 抗ｃｄ１００抗体およびこれを使用するための方法
JP5762408B2 (ja) 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
WO2011107586A1 (en) 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2580239A1 (de) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
TWI539963B (zh) 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
US9034333B2 (en) 2010-08-27 2015-05-19 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
WO2012032143A1 (en) 2010-09-10 2012-03-15 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Phosphorylated twist1 and metastasis
TR201812636T4 (tr) 2010-10-11 2018-09-21 Biogen Int Neuroscience Gmbh İnsan anti-tau antikorları.
EP2640738A1 (de) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antimykotische wirkstoffe
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
TWI700093B (zh) 2011-03-16 2020-08-01 法商賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
EP2773664A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49-antikörper
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
EP2776838A1 (de) 2011-11-08 2014-09-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Frühe diagnose neurodegenerativer erkrankungen
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US9416179B2 (en) 2011-12-05 2016-08-16 X-Body, Inc. PDGF receptor beta binding polypeptides
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
IN2014DN08199A (de) 2012-03-02 2015-05-01 Vaccinex Inc
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
HRP20180928T1 (hr) 2012-03-28 2018-07-27 Sanofi Protutijela za ligande bradikinin b1 receptora
EP2831112A1 (de) 2012-03-29 2015-02-04 Friedrich Miescher Institute for Biomedical Research Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
CA2872856A1 (en) 2012-05-07 2013-11-14 Sanofi Methods for preventing biofilm formation
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
MX369626B (es) 2012-05-24 2019-11-13 Mountgate Group Ltd Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia.
EP2866831A1 (de) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
CN104936980B (zh) 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
US20160002325A1 (en) 2013-03-08 2016-01-07 Vaccinex, Inc. Anti-cxcl13 antibodies and associated epitope sequences
NZ712300A (en) 2013-03-15 2020-07-31 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
KR20160035077A (ko) 2013-08-13 2016-03-30 사노피 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
CA2926089C (en) 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
EP3450571B1 (de) 2014-02-24 2023-04-05 Celgene Corporation Verfahren zur verwendung eines aktivators von cereblon für neuronale zellexpansion und behandlung von erkrankungen des zentralnervensystems
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106164094B (zh) 2014-03-21 2021-05-14 X博迪公司 双特异性抗原结合多肽
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
EP3154579A1 (de) 2014-06-13 2017-04-19 Friedrich Miescher Institute for Biomedical Research Neue behandlung gegen das influenzavirus
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
EP3164129A1 (de) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
EP3174898A2 (de) 2014-07-29 2017-06-07 Neurimmune Holding AG Vom menschen abgeleitete anti-huntingtin-(htt)-antikörper und verwendungen davon
US20170298360A1 (en) 2014-09-24 2017-10-19 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
CN108064248B (zh) 2014-09-30 2022-03-15 生物控股有限公司 人源抗二肽重复(dpr)抗体
CN107108054B (zh) 2014-10-31 2020-10-13 免疫医疗有限责任公司 改进的制造方法
AU2015360282B2 (en) 2014-12-11 2021-04-01 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
HUE053097T2 (hu) 2015-03-31 2021-06-28 Medimmune Ltd Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására
EP3349791A1 (de) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-zell-rezeptor-bindende antikörper und verwendungen davon
EP3368566A1 (de) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w und gallengangkrebs
ES2880731T3 (es) 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
EP3432925A4 (de) 2016-03-22 2019-11-06 Bionomics Limited Verabreichung eines monoklonalen anti-lgr5-antikörpers
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
MX2019013110A (es) 2017-05-05 2019-12-16 Vaccinex Inc Anticuerpo anti-semaforina 4d humano.
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
EP3717069A1 (de) 2017-11-27 2020-10-07 Purdue Pharma L.P. Gegen menschlichen gewebefaktor gerichtete humanisierte antikörper
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
KR20210126078A (ko) 2019-02-13 2021-10-19 더 브리검 앤드 우먼즈 하스피털, 인크. 항-말초 림프절 어드레신 항체 및 그의 용도
KR20210152472A (ko) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 Cd22 항체 및 이를 사용하는 방법
CA3135032A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
WO2020242989A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis
IL295980A (en) 2020-02-28 2022-10-01 Brigham & Womens Hospital Inc Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
AU2022208361A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Anti-dll3 antibody-drug conjugate
MX2023008261A (es) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
CN118696059A (zh) 2021-11-17 2024-09-24 美国全心医药生技股份有限公司 使用抗psgl-1抗体与jak抑制剂的组合治疗t细胞介导的炎症性疾病或癌症的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
ATE74382T1 (de) * 1984-12-05 1992-04-15 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
EP0282057A3 (de) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-Radio-Immunkonjugate
ATE87007T1 (de) * 1987-05-29 1993-04-15 Sagami Chem Res Fusionsprotein, enthaltend lymphotoxin.
ATE88900T1 (de) * 1987-09-02 1993-05-15 Ciba Geigy Ag Konjugate von interferon alpha mit immunglobulinen.
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy

Also Published As

Publication number Publication date
FI902245A0 (fi) 1990-05-04
DK0396387T3 (da) 1994-02-14
KR900017612A (ko) 1990-12-19
NO301168B1 (no) 1997-09-22
ZA902949B (en) 1992-02-26
IE63847B1 (en) 1995-06-14
NZ233413A (en) 1992-05-26
CA2015060A1 (en) 1990-11-05
HK1006678A1 (en) 1999-03-12
JP3589459B2 (ja) 2004-11-17
EP0396387B1 (de) 1993-12-22
ATE98873T1 (de) 1994-01-15
CN1047035A (zh) 1990-11-21
IL94167A0 (en) 1991-01-31
PT93966B (pt) 1996-12-31
PT93966A (pt) 1991-02-08
DE69005352D1 (de) 1994-02-03
CN1072505C (zh) 2001-10-10
EP0396387A3 (de) 1991-04-03
NO901986D0 (no) 1990-05-04
AU645747B2 (en) 1994-01-27
EP0396387A2 (de) 1990-11-07
IE901405L (en) 1990-11-05
AU5379590A (en) 1990-11-08
KR0181294B1 (ko) 1999-03-20
DE69005352T2 (de) 1994-04-14
FI100092B (fi) 1997-09-30
SA90110099B1 (ar) 2004-02-15
NO901986L (no) 1990-11-06
ES2060947T3 (es) 1994-12-01
JPH02306923A (ja) 1990-12-20
CA2015060C (en) 2008-03-18

Similar Documents

Publication Publication Date Title
IL94167A (en) Immunoconjugate targeting 15A8 or ZME-018 antigens and comprising TNF or interleukin-1
CA2078118A1 (en) Cc-1065 analogs
KR950016781A (ko) 면역접합체
EG15882A (en) Procede de preparation de nouveaux conjuges associants,par liaison covalente,une enzyme et un anticorps
CA2131528A1 (en) Methods and compositions for targeting the vasculature of solid tumors
EP0536275A4 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
IL111914A0 (en) Immunoconjugates containing an antibody fragment, processes for the preparation thereof, and pharmaceutical and diagnostic compositions containing thesame
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
CA2399866A1 (en) Compositions and methods for treatment of angiogenesis in pathological lesions
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
CA2284079A1 (en) Immunotoxins and methods of inducing immune tolerance
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
Jinno et al. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF—ribonuclease conjugate on human cancer cell lines-A trial for less immunogenic chimeric toxin- -A trial for less immunogenic chimeric toxin
AU665763B2 (en) Interleukin receptor targeted molecules for treatment of inflammatory arthritis
Tsukada et al. Therapeutic effect of treatment with polyclonal or monoclonal antibodies to α-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an α-fetoprotein-producing rat hepatoma tumor model
EP0194851A3 (de) Therapie der menschlichen Tumore
Wawrzynczak et al. Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
US4356117A (en) Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells
WO1996032137A3 (en) Methods of inducing immune tolerance using immunotoxins
MY103231A (en) Immunoglobulin conjugates
Villemez et al. Preparation of an immunotoxin for Acanthamoeba castellanii
Li et al. Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-erbB-2 product

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired